Citations

Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 94 (6):1259-1276.

Wang YJ, Huang JP, Tian T, Yan Y, Chen Y, Yang J, Chen J, Gu YC, Huang SX. 2022. Discovery and Engineering of the Cocaine Biosynthetic Pathway. J Am Chem Soc. 144 (48):22000-22007.

Clarke HT, Rahrs EJ. 1923. Benzoic Anhydride. Org Synth. 3:21.

Kamble VM, Gharge MS. 2019. Synthesis of Acetic Anhydride by using Phosphorous Pentoxide, Sodium Acetate and Calcium Chloride as a Catalyst. IJRASET, 7 (VIII). :852-857.

Chemiday. 2015. Ethanol react with hydrogen iodide.

Lombardo F, Obach RS, Shalaeva MY, Gao F. 2004. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. J Med Chem. 47 (5):1242-1250.

Charman SA, Andreu A, Barker H, Blundell S, Campbell A, Campbell M, Chen G, Chiu FCK, Crighton E, Katneni K et al. 2020. An in vitro toolbox to accelerate anti-malarial drug discovery and development. Malar J. 19 (1):1.

Walker O, Birkett DJ, Alván G, Gustanfsson LL, Sjöqvist F. 1983. Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol. 15 (3):375-377.

Eyles DW, Stedman TJ, Pond SM. 1994. Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms. Psychopharmacology (Berl). 116 (2):161-166.

Cloyd JC, Dutta S, Cao G, Walch JK, Collins SD, Granneman GR, Depacon Study Group. 2003. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 53 (1-2):19-27.

Colthup PV, Palmer JL. 1989. The determination in plasma and pharmacokinetics of ondansetron. Eur J Cancer Clin Oncol. 25 (Suppl 1):71-74.

Singhvi SM, Pan HY, Morrison RA, Willard DA. 1990. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 29 (2):239-243.

Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. 2003. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 73 (6):538-544.

Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H. 1992. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol. 32 (2):124-132.

Salna MP, Singer HM, Dana AN. 2017. Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis. Case Rep Dermatol Med. 2017 .

Wan Aasim WR, Tan SC, Gan SH. 2017. Interspecies In Vitro Evaluation of Stereoselective Protein Binding for 3,4-Methylenedioxymethamphetamine. J Chem. 2017 .

Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TY. 1994. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 47 (7):1151-1156.

Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. 1997. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 53 (11):1605-1612.

Argikar UA, Remmel RP. 2009. Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 39 (5):355-363.

Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. 1987. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther. 42 (5):535-541.

Foord RD. 1976. Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother. 9 (5):741-747.

Lin JH, Chremos AN, Yeh KC, Antonello J, Hessey 2nd GA. 1988. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. Eur J Clin Pharmacol. 34 (1):41-46.

Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N et al. 1985. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. Eur J Clin Pharmacol. 28 (3):327-331.

Yeh KC, Chremos AN, Lin JH, Constanzer ML, Kanovsky SM, Hucker HB, Antonello J, Vlasses P, Ryan JR, Williams RL. 1987. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. Biopharm Drug Dispos. 8 (6):549-560.

Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. 1981. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 12 (2):235-246.

Regårdh CG, Borg KO, Johansson R, Johnsson G, Palmer R. 1974. Pharmacokinetic studies on the selective β1-receptor antagonist metoprolol in man. Journal of Pharmacokinetics and Pharmacodynamics. 2:347-364.

Lukacova V, Woltosz WS, Bolger MB. 2009. Prediction of Modified Release Pharmacokinetics and Pharmacodynamics from In Vitro, Immediate Release, and Intravenous Data. AAPS J. 11 (2):323-334.